compounded semaglutide ban update FDA on GLP-1 Drugs: What to Know The FDA Just Banned Compounded

GLP-1 secretion is increased by inflammatory stimuli in an IL-6-dependent manner, leading to hyperinsulinemia and blood glucose lowering

Pipeline Innovation and Next-Generation Drugs Next-generation GLP-1 treatments with increased efficacy, fewer side effects, and more convenient dosing options are attracting significant investment from pharmaceutical companies

Unlike GHRP-2 or GHRP-6, research demonstrates that Ipamorelin does not stimulate the release of Adrenocorticotropic Hormone (ACTH), Cortisol, or Prolactin, even at high saturation levels

A range of mast cell disorders can overlap with other acute and chronic illnesses

Cells 13(4):296 Smith L, Schapira AH (2022) GBA variants and Parkinson disease: mechanisms and treatments

However, additional pharmacological studies are needed to improve the treatment efficacy in terms of dose, route of administration or combination of administered drugs